Yago Garitaonaindía, Professor at University of Copenhagen (Københavns Universitet), shared a post on X:
“Our new paper in JNCI: do reimbursed drugs deliver in routine care what trials promised?
A new framework quantifies the efficacy-effectiveness gap from a national registry (DAMMED).
In melanoma:
- IO deviated only in ineligible pts (HR 1.61)
- Targeted therapy deviated even in eligible ones
The method is exportable to any registry-backed disease.
Senior and corresponding – Marco Donia.”
Title: Quantifying the efficacy-effectiveness gap in first line treatment of metastatic melanoma
Authors: Yago Garitaonaindia, Adam A Luczak, Christina H Ruhlmann, Søren Kjær Petersen, Rasmus Blechingberg Friis, Troels H Borch, Louise M Guldbrandt, Inge Marie Svane, Henrik Schmidt, Lars Bastholt, Eva Ellebaek, Marco Donia.
Other articles featuring Yago Garitaonaindía on OncoDaily.
